Inhibitor Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

INTI

organization

SIC: 2834

SEC Insider

$195.20B

205 transactions

Summary

Inhibitor Therapeutics, Inc. (INTI) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $195.19BSales: $3.3M29 insiders

Date	Insider	Type	Value
2026-05-05	Vasisht Niraj	A	$0
2026-05-04	Jerman Michael Allen	A	$0
2025-04-01	Jerman Michael Allen	A	$0
2025-04-01	Joint reporting: OSMAN RONALD E; Ronald E Osman Irrevocable Trust III	A	$0
2025-04-01	SEARS SAMUEL P JR	A	$0
2025-04-01	Yanez Michelle	A	$0
2025-04-01	Vasisht Niraj	A	$0
2024-12-02	Yanez Michelle	G	$0
2024-12-02	MCNULTY JAMES A(Chief Financial Officer)	G	$0
2024-04-01	Jerman Michael Allen	A	$0
2024-04-01	Yanez Michelle	A	$0
2024-04-01	Joint reporting: OSMAN RONALD E; Ronald E Osman Irrevocable Trust III	A	$0
2024-04-01	SEARS SAMUEL P JR	A	$0
2024-03-16	MCNULTY JAMES A(CHIEF FINANCIAL OFFICER)	A	$0
2023-08-11	Joint reporting: OSMAN RONALD E; Ronald E Osman Irrevocable Trust III	A	$0
2023-05-05	Yanez Michelle	J	$0
2023-05-05	MCNULTY JAMES A(See Remarks)	J	$0
2023-05-05	MCNULTY JAMES A(See Remarks)	J	$0
2023-05-05	MCNULTY JAMES A(See Remarks)	J	$0
2021-01-15	Joint reporting: Mayne Pharma Group Ltd; Mayne Pharma International Pty Ltd; Mayne Pharma Ventures Pty Ltd	J	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Inhibitor Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope